APA

Armstrong A., Bui C., Fitch K., Sawhney T. G., Brown B., Flanders S., Balk M., Deangelis J. & Chambers J. (20171229). Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. : Current medical research and opinion.

Chicago

Armstrong A, Bui C, Fitch K, Sawhney T Goss, Brown B, Flanders S, Balk M, Deangelis J and Chambers J. 20171229. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. : Current medical research and opinion.

Harvard

Armstrong A., Bui C., Fitch K., Sawhney T. G., Brown B., Flanders S., Balk M., Deangelis J. and Chambers J. (20171229). Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. : Current medical research and opinion.

MLA

Armstrong A, Bui C, Fitch K, Sawhney T Goss, Brown B, Flanders S, Balk M, Deangelis J and Chambers J. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. : Current medical research and opinion. 20171229.